Biotech Values

[RNsidersbuying]

ARDX 1.60 - https://ritzherald.com/specialty-physicians-weigh-in-with-opinions-about-the-u-s-food-and-drug-administration/

Nephrologists are not far behind in their dismay and disappointment, struggling with recent events that are likely to keep two novel therapeutics, Fibrogen/AstraZeneca’s roxadustat and Ardelyx’s tenapanor, from reaching patients. Sheldon Shore, MD, a practicing nephrologist in Atlanta weighed in, “The FDA needs to work harder to help us get these new drugs approved for use in our patients. I feel it has gotten too political, making it harder and harder for new drugs to get approved.”